Sort by
Refine Your Search
-
. About Eidos and BridgeBio Pharma Inc. BridgeBio Pharma, Inc. (BridgeBio/BBIO) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who
-
team that’s earned trust for more than two centuries, and find out how advancing transformative therapies at Takeda will shape your bright future. Responsibilities · Regulatory Strategy Development
-
neurodegenerative diseases. 5. Oncomechanobiology: this area focuses on mechanobiological basis of development, stem cells, and cancer, with the aim to discover new pathways of intervention in pathological conditions
-
vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. CSL Seqirus
-
. Tracking cerebrovascular health in at-risk, but cognitively normal individuals will greatly facilitate early detection of those most at risk of developing dementia, allowing the opportunity for early
-
. Learning Objectives: Develop deep expertise in the principles and practices of scientific and medical communications. Understand the strategic role of communications in product lifecycle management. Gain
-
development to prepare fellows for a successful career in the pharmaceutical industry. Learning Objectives: Develop deep expertise in the principles and practices of scientific and medical communications
-
status, disability, or any other characteristics prohibited by law. Responsibilities Overview Global Patient Safety and Risk Management (GPSRM) oversees all activities related to the detection, assessment
-
of their choice, with options including Scientific Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: Develop in-depth knowledge
-
Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: · Develop in-depth knowledge of Intellia’s CRISPR gene editing technology